In a Phase 3 clinical trial, collaborators GlaxoSmithKline (GSK - TopicsExpress



          

In a Phase 3 clinical trial, collaborators GlaxoSmithKline (GSK -2.4%) and Gilead Sciences (GILD +0.5%) report that the combination therapy of Gileads Letairis (ambrisentan) and tadalafil (Adcirca) reduced the risk of clinical failure by 50% in patients with pulmonary arterial hypertension (PAH) compared to the pooled ambrisentan and tadalafil monotherapy arm. The results are statistically significant for the primary endpoint of the time to the first clinical failure event. The results are being presented today during an oral session at the European Respiratory Society International Congress in Munich, Germany.
Posted on: Mon, 08 Sep 2014 21:05:18 +0000

Trending Topics



Recently Viewed Topics




© 2015